ArticleJournal of cosmetic dermatology2026
Hyperdiluted Triamcinolone Injections for Nasal and Alar Contouring.
Article in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDemand for minimally invasive nasal contour refinement has increased, particularly among patients seeking subtle esthetic improvement without surgery or volume augmentation. While hyaluronic acid filler-based nonsurgical rhinoplasty can alter contour, it fundamentally adds volume and carries rare but severe vascular risks. In contrast, intralesional corticosteroids are known to induce localized soft-tissue thinning and have been used in postoperative rhinoplasty to manage supratip fullness, suggesting a potential role in nonsurgical soft-tissue contour modulation.
objectiveTo describe a nonsurgical, nonfiller technique using hyperdiluted triamcinolone acetonide (TAC) microinjections for targeted reduction of nasal and alar soft-tissue fullness, and to present a structured case-series protocol with standardized Global Aesthetic Improvement Scale (GAIS) reporting.
resultsTwenty adult patients underwent a standardized 10-point microinjection protocol using hyperdiluted TAC (approximately 1.3 mg/mL), with 1.0 mL administered per session and sessions repeated every 3 weeks for a total of five sessions. The cumulative TAC dose per patient was approximately 6.5 mg. Outcomes were assessed using patient-reported GAIS at final follow-up. This manuscript provides a patient-level GAIS reporting framework and an illustrative results table to support transparent outcome documentation. The technique is conceptually distinct from surgical rhinoplasty and filler-based approaches, aiming for gradual, localized soft-tissue thinning through dose-minimized, distributed corticosteroid exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.